As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
Therapeutic antibodies have advanced modern medicine, but creating successful new therapeutics is far from straightforward. From understanding complex molecular interactions and engineering antibodies with the right properties to evaluating candidates and exploring new therapeutic formats, researchers are tackling difficult scientific questions across discovery and development.
This expert panel brings together leading researchers from academia and industry to explore where the field is making progress, which scientific challenges remain and what it takes to advance new therapeutics. The discussion will examine the complex science behind their discovery and development, including the opportunities and challenges presented by antibody–drug conjugates.
What you’ll learn:
- Explore where therapeutic antibody research is making progress and which scientific problems remain hardest to solve
- Understand current approaches to antibody engineering and therapeutic development
- Examine how antibody structure, function and molecular interactions inform therapeutic research and development
- Discover advances in antibody-based therapeutics, including antibody–drug conjugates.
Whether you work in antibody discovery, engineering or therapeutic development, you’ll leave with a clearer understanding of where the field is making progress, the scientific questions still to be answered and where the greatest opportunities lie.
SECURE YOUR SPOT TODAY!
Meet the panel:
Professor Simon Davis – Professor of Molecular Immunology, University of Oxford
Professor Simon Davis is Professor of Molecular Immunology at the University of Oxford and leads a laboratory investigating how lymphocyte receptors, including immune checkpoints, are triggered. He joined the MRC Cellular Immunology Unit at Oxford in 1987, where he focused on T-cell surface biology, before establishing his own laboratory in 1995.
He is currently based at the MRC Weatherall Institute of Molecular Medicine and is a member of the MRC Translational Immune Discovery Unit. His research focuses on the molecular mechanisms governing immune receptor function, using structural and functional approaches to better understand cell surface biology and immune regulation.
Dr Jean-Philippe Julien – Canada Research Chair in Structural Immunology at the Hospital for Sick Children Research Institute and the University of Toronto
Dr Jean-Philippe Julien is Canada Research Chair in Structural Immunology at the Hospital for Sick Children Research Institute and the University of Toronto. He leads a multidisciplinary research team investigating the molecular characteristics of antibodies and their interactions with viral, bacterial, parasitic and cell-surface antigens.
His laboratory uses structural approaches to understand antibody recognition and provide atomic-level insights that can support the development of new therapeutics and vaccines. Prof Julien completed his PhD at the University of Toronto and postdoctoral training at The Scripps Research Institute. He is also a Member of the College of the Royal Society of Canada.
Professor Klaus Pors – Professor of Chemical Biology, University of Bradford
Professor Klaus Pors is Professor of Chemical Biology at the University of Bradford, where his research focuses on cancer pharmacology, chemical biology and the development of tumour-selective therapies. His work includes the discovery of anticancer agents targeting drug-resistant cancers and the development of prodrugs for hypoxic tumours.
He joined the Institute of Cancer Therapeutics in 2005 as a Yorkshire Cancer Research-funded lecturer and team leader. Prof Pors has experience working with start-up and biotechnology companies, licensing technologies and developing patented innovations. He holds a BEng in Chemical Engineering from the University of Southern Denmark and completed his PhD and postdoctoral research at the UCL School of Pharmacy.
Professor Anna Lippert – Professor of Systems Immunology at the University of Würzburg
Prof Anna Lippert is Professor of Systems Immunology at the University of Würzburg, where her research focuses on how immune cells perceive and respond to their physical environment. Her group uses single-molecule, traction force and confocal microscopy to investigate how the stiffness of surrounding tissues influences immune cell migration and activation.
Lippert’s research interests include T-cell mechanosensing in lymph nodes, the role of actin conformation in T-cell activation and mechanosensing and autoantibodies in autoimmune diseases. Her work aims to improve understanding of immune cell behaviour and provide a basis for more targeted approaches to treating cancer and immune diseases.
Further expert panellists to be announced.
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
The webinar will be taking place on [insert date and time]
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.